Antibacterial Small Molecules, Vaccines for UTI

Sequoia Vaccines Inc. is a clinical-stage pharmaceutical company dedicated to developing innovative vaccines and small molecule therapies aimed at preventing bacterial infections and treating certain cancers. Their lead program, SEQ-400, is a FimH vaccine designed to prevent recurrent urinary tract infections (UTIs), particularly those caused by multidrug-resistant bacteria. This vaccine has received FDA fast-track designation and has shown promising results in clinical trials, demonstrating a significant immune response and a reduction in UTI occurrences among participants. The company is also advancing a small molecule drug platform, SEQ-1274, targeting ovarian and other cancers, which highlights their commitment to addressing serious health challenges through novel therapeutic approaches.

In addition to their UTI and cancer programs, Sequoia Vaccines is optimizing small molecule compounds for the treatment of lung infections associated with cystic fibrosis. These compounds aim to inhibit bacterial biofilms that can severely impact lung function in affected patients. The company’s research and development efforts are supported by a strong leadership team with extensive experience in pharmaceutical research and development, as well as a scientific advisory board comprising experts in the field. Sequoia Vaccines is focused on addressing unmet medical needs through their innovative pipeline, which is designed to combat antimicrobial resistance and improve patient outcomes in various therapeutic areas.

United States

Formed in 2012 Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of a novel vaccine to prevent bacterial infections, including recurrent urinary tract infections (UTIs) and the treatment of certain cancers and lung infections associated with cystic fibrosis with small molecules.

Sequoia Vaccines Inc

Company Details